These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 30609891)

  • 1. Multitarget 1,4-Dioxane Compounds Combining Favorable D
    Del Bello F; Ambrosini D; Bonifazi A; Newman AH; Keck TM; Giannella M; Giorgioni G; Piergentili A; Cappellacci L; Cilia A; Franchini S; Quaglia W
    ACS Chem Neurosci; 2019 May; 10(5):2222-2228. PubMed ID: 30609891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine.
    Kiss B; Némethy Z; Fazekas K; Kurkó D; Gyertyán I; Sághy K; Laszlovszky I; Farkas B; Kirschner N; Bolf-Terjéki E; Balázs O; Lendvai B
    Drug Des Devel Ther; 2019; 13():3229-3248. PubMed ID: 31571826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. F15063, a potential antipsychotic with dopamine D2/D3 receptor antagonist, 5-HT1A receptor agonist and dopamine D4 receptor partial agonist properties: influence on neuronal firing and neurotransmitter release.
    Assié MB; Mnie-Filali O; Ravailhe V; Benas C; Marien M; Bétry C; Zimmer L; Haddjeri N; Newman-Tancredi A
    Eur J Pharmacol; 2009 Apr; 607(1-3):74-83. PubMed ID: 19326477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats.
    Oyamada Y; Horiguchi M; Rajagopal L; Miyauchi M; Meltzer HY
    Behav Brain Res; 2015 May; 285():165-75. PubMed ID: 25448429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New arylpiperazinylalkyl derivatives of 8-alkoxy-purine-2,6-dione and dihydro[1,3]oxazolo[2,3-f]purinedione targeting the serotonin 5-HT1A /5-HT2A /5-HT7 and dopamine D2 receptors.
    Chłoń-Rzepa G; Zagórska A; Bucki A; Kołaczkowski M; Pawłowski M; Satała G; Bojarski AJ; Partyka A; Wesołowska A; Pękala E; Słoczyńska K
    Arch Pharm (Weinheim); 2015 Apr; 348(4):242-53. PubMed ID: 25773907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and evaluation of benzo[a]thieno[3,2-g]quinolizines as novel l-SPD derivatives possessing dopamine D1, D2 and serotonin 5-HT1A multiple action profiles.
    Li Z; Huang J; Sun H; Zhou S; Guo L; Zhou Y; Zhen X; Liu H
    Bioorg Med Chem; 2014 Nov; 22(21):5838-46. PubMed ID: 25308766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and Pharmacology of the enantiomers of the potential atypical antipsychotic agents 5-OMe-BPAT and 5-OMe-(2,6-di-OMe)-BPAT.
    Homan EJ; Copinga S; Unelius L; Jackson DM; Wikström HV; Grol CJ
    Bioorg Med Chem; 1999 Jul; 7(7):1263-71. PubMed ID: 10465402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.
    Depoortère R; Bardin L; Auclair AL; Kleven MS; Prinssen E; Colpaert F; Vacher B; Newman-Tancredi A
    Br J Pharmacol; 2007 May; 151(2):253-65. PubMed ID: 17375086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of novel dopamine D
    Zhang C; Li Q; Meng L; Ren Y
    J Biomol Struct Dyn; 2020 Feb; 38(3):860-885. PubMed ID: 30916624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological investigation of new equatorial (β) stereoisomers of 3-aminotropane arylamides with atypical antipsychotic profile.
    Stefanowicz J; Słowiński T; Wróbel MZ; Herold F; Gomółka AE; Wesołowska A; Jastrzębska-Więsek M; Partyka A; Andres-Mach M; Czuczwar SJ; Łuszczki JJ; Zagaja M; Siwek A; Nowak G; Żołnierek M; Bączek T; Ulenberg S; Belka M; Turło J
    Bioorg Med Chem; 2016 Sep; 24(18):3994-4007. PubMed ID: 27377863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5-HT)2A and DA D2 antagonism and 5-HT1A partial agonism.
    Huang M; Panos JJ; Kwon S; Oyamada Y; Rajagopal L; Meltzer HY
    J Neurochem; 2014 Mar; 128(6):938-49. PubMed ID: 24164459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotonin receptors: their key role in drugs to treat schizophrenia.
    Meltzer HY; Li Z; Kaneda Y; Ichikawa J
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1159-72. PubMed ID: 14642974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade.
    Auclair AL; Kleven MS; Besnard J; Depoortère R; Newman-Tancredi A
    Neuropsychopharmacology; 2006 Sep; 31(9):1900-9. PubMed ID: 16421514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual ligands targeting dopamine D2 and serotonin 5-HT1A receptors as new antipsychotical or anti-Parkinsonian agents.
    Ye N; Song Z; Zhang A
    Curr Med Chem; 2014; 21(4):437-57. PubMed ID: 24164194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence on the New Drug Lumateperone (ITI-007) for Psychiatric and Neurological Disorders.
    Mazza M; Marano G; Traversi G; Sani G; Janiri L
    CNS Neurol Disord Drug Targets; 2020; 19(4):243-247. PubMed ID: 32479249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of different monoamine receptors controlling MK-801-induced release of serotonin and glutamate in the medial prefrontal cortex: relevance for antipsychotic action.
    López-Gil X; Artigas F; Adell A
    Int J Neuropsychopharmacol; 2009 May; 12(4):487-99. PubMed ID: 18752722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. III. Activity in models of cognition and negative symptoms.
    Depoortère R; Auclair AL; Bardin L; Bruins Slot L; Kleven MS; Colpaert F; Vacher B; Newman-Tancredi A
    Br J Pharmacol; 2007 May; 151(2):266-77. PubMed ID: 17375085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The replacement of the 2-methoxy substituent of N-((6,6-diphenyl-1,4-dioxan-2-yl)methyl)-2-(2-methoxyphenoxy)ethan-1-amine improves the selectivity for 5-HT
    Del Bello F; Bonifazi A; Giannella M; Giorgioni G; Piergentili A; Petrelli R; Cifani C; Micioni Di Bonaventura MV; Keck TM; Mazzolari A; Vistoli G; Cilia A; Poggesi E; Matucci R; Quaglia W
    Eur J Med Chem; 2017 Jan; 125():233-244. PubMed ID: 27662034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D
    Dedic N; Jones PG; Hopkins SC; Lew R; Shao L; Campbell JE; Spear KL; Large TH; Campbell UC; Hanania T; Leahy E; Koblan KS
    J Pharmacol Exp Ther; 2019 Oct; 371(1):1-14. PubMed ID: 31371483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine D4 receptors and development of newer antipsychotic drugs.
    Kulkarni SK; Ninan I
    Fundam Clin Pharmacol; 2000; 14(6):529-39. PubMed ID: 11206702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.